{"schema":"sb.node.v1","id":"sb:e/e20001c47e40d4b109d5f837","kind":"entity","label":{"text":"immunotherapy","locale":"en"},"identity":{"anchor":"label:en:immunotherapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-29T23:27:11.436223+00:00","releaseId":"sb-b15196466688","snapshot":"deploy abbb7d522cc6e1dbc7093813951f4bfb83b36895"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":742,"separatePublishers":167,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.497,"named":369,"of":742,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 50% of the 742 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-11","to":"2026-10-27","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.049: about 95% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","pubmed_targeted"],"activeDays":145,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/b138bb6bfcea5491f70e208a","kind":"observation","label":"Seoul Economic Daily · 2026-10-27 · Samsung Bioepis Keytruda Biosimilar Matches Original in Phase 1 Trial","url":"https://en.sedaily.com/culture/2026/10/27/samsung-bioepis-keytruda-biosimilar-matches-original-in","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/89f7f9d1b6fd8a4d71fd2bb4","kind":"observation","label":"Medical Xpress · 2026-10-27 · Exploring the potential of immunotherapy in early-stage triple-negative breast cancer","url":"https://medicalxpress.com/news/2026-10-exploring-potential-immunotherapy-early-stage.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/a8effcccb934ea25b8db9e95","kind":"observation","label":"European Medical Journal · 2026-10-25 · PSGL-1 Shows Promise as Cancer immunotherapy Target","url":"https://www.emjreviews.com/oncology/news/psgl-1-shows-promise-as-cancer-immunotherapy-target/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/67f616ec45c63eb4d1fe2a78","kind":"observation","label":"OncoDaily · 2026-10-25 · PERSEE: Adding Chemotherapy to Pembrolizumab Significantly Extends PFS in PD-L1–High NSCLC","url":"https://oncodaily.com/oncolibrary/lung-oncology/persee-esmo26","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/4b5407622cb21f9831bb9eab","kind":"observation","label":"OncoDaily · 2026-10-25 · OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab Outperforms Chemoimmunotherapy in PD-L1–Negative NSCLC","url":"https://oncodaily.com/oncolibrary/lung-oncology/optitrop-lung06-esmo26","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/0f18a9f33354909abbd65900","kind":"observation","label":"Medical Daily · 2026-10-25 · Adding Belzutifan or a CTLA-4 Drug Failed to Beat Keytruda Plus Lenvima in 1,688-Patient Kidney Cancer Trial","url":"https://www.medicaldaily.com/litespark-012-kidney-cancer-keytruda-lenvima-triplet-results-480407","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/82ffdba9365dde9414f168a2","kind":"observation","label":"medRxiv Oncology · 2026-10-24 · USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366185v1?rss=1","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/d12308fb966cfe805709d2af","kind":"observation","label":"Peter Attia · 2026-10-24 · Personalized medicine comes to cancer immunotherapy","url":"https://peterattiamd.com/personalized-medicine-comes-to-cancer-immunotherapy/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/6fd50f291b2496cc382ec7e2","kind":"observation","label":"The Medical News · 2026-10-24 · Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy","url":"https://www.news-medical.net/news/20261024/Personalized-mRNA-cancer-vaccine-cuts-melanoma-recurrence-risk-when-added-to-immunotherapy.aspx","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/7ce66757b6c45e5107afff00","kind":"observation","label":"The Medical News · 2026-10-24 · Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy","url":"https://www.news-medical.net/news/20261024/Nearly-one-third-of-patients-with-advanced-melanoma-saw-tumors-disappear-completely-after-receiving-TIL-therapy-plus-pembrolizumab-immunotherapy.aspx","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTI5VDIzOjI3OjExLjQzNjIyMyswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":12,"byKind":{"claim":2,"co-mentioned":10},"items":[{"id":"sb:p/645cb04c093b1e854129ef6f","kind":"claim","label":"Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy — reported by two","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/931dff2e10e008950adf4e74","kind":"claim","label":"New biomarker framework proposed for immunotherapy in microsatellite-stable colorectal cancer — could not check","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (330 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0725cc3ec034d8655a343f00"},{"kind":"relation","label":"co-mentioned with overall survival (170 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c39aa535642ecb09f7fc34bf"},{"kind":"relation","label":"co-mentioned with fda (161 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7452689d97c7c885406e799d"},{"kind":"relation","label":"co-mentioned with lung cancer (148 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/27c8d6ca13365be381edf726"},{"kind":"relation","label":"co-mentioned with china (108 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb9e3f039eba6f25b268eee0"},{"kind":"relation","label":"co-mentioned with merck (99 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e7bd02adf1bffa8ec3cf2f01"},{"kind":"relation","label":"co-mentioned with t-cell (97 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/90bb905c886825b7846113cc"},{"kind":"relation","label":"co-mentioned with clinical trial (95 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9484f7f975002eb0509f095e"}],"cursor":"c1.eyJpZCI6InNiOmUvZTIwMDAxYzQ3ZTQwZDRiMTA5ZDVmODM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0yOVQyMzoyNzoxMS40MzYyMjMrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/e20001c47e40d4b109d5f837","mcp":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}","page":"/entity/immunotherapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/e20001c47e40d4b109d5f837\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}